A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism; Metabolic syndrome
- Focus Pharmacodynamics
- 13 May 2010 Interim results were presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy).
- 09 Jul 2008 New trial record.